Yes. 11 FDA-approved labels for Pioglitazone carry a boxed warning, and its subject is congestive heart failure. A boxed warning is the most serious warning the FDA requires on a prescription label. It is applied to the drug and to the situations in which it is used, not to any particular person taking it.
What the warning says
Below is how the Pioglitazone warning opens on one specific label, identified underneath it. Of the 11 Pioglitazone labels sampled, 3 carried materially different wordings, and this was the most common, used by 8 of them.
WARNING: CONGESTIVE HEART FAILURE Thiazolidinediones, including pioglitazone , cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1) ] . After initiation of pioglitazone , and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone must be considered. Pioglitazone is not recommended in patients with symptomatic heart failure.
PIOGLITAZONE HYDROCHLORIDE, QUALLENT PHARMACEUTICALS HEALTH LLC, label version effective 17 May 2025. Opening of the warning; read the full label on DailyMed.Why the wording differs between manufacturers
There is no single official text of a boxed warning. The FDA sets what a warning must cover, and each manufacturer writes its own label within that. Of the 11 Pioglitazone labels sampled for this page, 3 carried materially different wordings of the same warning, and the version quoted above was used by 8 of them.
The hazard does not change between those 3 versions. Only the sentences do, which is why a refill from a different manufacturer can carry warning text that reads differently without anything about Pioglitazone or its risks having changed.
Pioglitazone is dispensed under 11 current FDA labels despite this warning, which is the point worth holding onto: a boxed warning is a disclosure requirement, not a verdict. What a boxed warning does and does not mean sets out the distinction.
Common questions
Does Pioglitazone have a black box warning?
Yes. 11 FDA-approved labels for Pioglitazone carry a boxed warning, and its subject is congestive heart failure. A boxed warning is the strongest warning the FDA requires on a prescription label, and it is applied to the drug, not to any individual taking it.
What does the Pioglitazone boxed warning say?
The wording is set by each manufacturer within FDA requirements, so it varies. In the version quoted on this page, taken from a label effective 17 May 2025, the warning concerns congestive heart failure. The full text is linked so the exact version can be read rather than summarised.
Does the Pioglitazone boxed warning mean the drug is unsafe or being withdrawn?
No. It means the FDA requires the risk of congestive heart failure to be communicated prominently so prescribers weigh it explicitly. Pioglitazone remains FDA-approved and is dispensed under 11 current labels. A boxed warning is a disclosure requirement, not a judgement that a drug should not be used.
Why do different pharmacies show different warning text for the same drug?
Because each manufacturer writes its own label within the FDA's requirements. Of 11 Pioglitazone labels sampled here, 3 carried materially different wordings of the same warning. The hazard described is the same; the sentences are not. This is a common source of confusion when a prescription is refilled with a different manufacturer's product.
Should I stop taking Pioglitazone because of this warning?
This page does not answer that and cannot. The warning about congestive heart failure is written for a prescriber deciding whether Pioglitazone suits a particular patient, and stopping a prescribed medicine carries its own risks that this page knows nothing about. Raise it with the prescriber or a pharmacist, who can see the whole picture.
Where this page's information comes from
The quotation above is from one Pioglitazone label, linked below by its DailyMed set identifier so the exact version can be opened rather than taken on trust. The figure of 11 labels, and the count of 3 distinct wordings among 11 sampled, were computed from the openFDA labelling API on 30 August 2026.
- PIOGLITAZONE HYDROCHLORIDE prescribing information, QUALLENT PHARMACEUTICALS HEALTH LLC, effective 17 May 2025.
- openFDA drug labelling API, the source of the label counts and variant counts on this page.
Labels are revised over time. The version linked above is the one this page was written against, and a newer revision may differ. Counts reflect the labels present in openFDA on the retrieval date.